Anne Wojcicki is at it again. After a failed attempt to buy back the DNA testing company she cofounded, the CEO has made another offer to gain control of 23andMe. But if the sale goes through, it’s bound to be controversial.
Wojcicki recently teamed up with New Mountain Capital, a venture capital firm, to propose buying out the struggling company’s shareholders at $2.53 per share, valuing the company at $74.7 million—a surprising price for a biotech firm that was worth $6 billion just four years ago.
